Want to see ALDX full AI Analyst Report?
Top Page
Aldeyra Therapeutics
(NASDAQ:ALDX)
Select Model
Select Model
Rating:48Neutral
Price Target:
$2.50
▲(38.89% Upside)
Action:Reiterated
Date:07/02/26
The score is held down primarily by weak financial performance (no revenue, continued losses, and historical cash burn with questions around the durability of the TTM cash-flow swing). Technicals provide some near-term momentum but show overbought signals and a weaker longer-term trend. Corporate updates and runway extension are supportive, while valuation remains constrained by negative earnings and no dividend.
Positive Factors
Extended cash runway to 2028
Management disclosing a cash runway to 2028 provides multi-year funding visibility to advance reproxalap programs and other RASP programs. This reduces near-term financing pressure, lowers immediate dilution risk, and gives time to generate regulatory readouts or partner deals that can materially change funding needs.
Negative Factors
No commercial revenue
As a clinical-stage biotech with no recurring product sales, Aldeyra depends on external financing to fund R&D and operations. This structural dependence creates dilution risk and ties execution to capital markets and milestone realization until a product generates sustainable revenues.
Read all positive and negative factors
Positive Factors
Negative Factors
Extended cash runway to 2028
Management disclosing a cash runway to 2028 provides multi-year funding visibility to advance reproxalap programs and other RASP programs. This reduces near-term financing pressure, lowers immediate dilution risk, and gives time to generate regulatory readouts or partner deals that can materially change funding needs.
Read all positive factors
Aldeyra Therapeutics (ALDX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$118.23M
Dividend YieldN/A
Average Volume (3M)1.04M
Price to Earnings (P/E)―
Beta (1Y)2.58
Revenue GrowthN/A
EPS Growth53.00%
CountryUS
Employees8
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.46
Shares Outstanding60,321,068
10 Day Avg. Volume1,169,475
30 Day Avg. Volume1,038,564
Financial Highlights & Ratios
PEG Ratio0.23
Price to Book (P/B)7.03
Price to Sales (P/S)0.00
P/FCF Ratio-9.33
Enterprise Value/Market Cap0.52
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-472.51
Enterprise Value/Ebitda-2.41
Forecast
1Y Price Target
$2.00Price Target Upside11.11% Upside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-0.41
Revenue Forecast (FY)$21.72M
Aldeyra Therapeutics Business Overview & Revenue Model
Company Description
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinica...
How the Company Makes Money
Aldeyra is not known to have a commercialized product generating recurring product sales; as a clinical-stage biotech, it primarily funds operations through capital raising (e.g., public equity offerings) and other financing activities rather than...
Aldeyra Therapeutics Financial Statement Overview
Summary
Income Statement
9
Very Negative
Balance Sheet
57
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -128.88K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -25.22M | -31.69M | -53.68M | -35.21M | -60.07M | -55.77M |
| Net Income | -27.37M | -33.85M | -55.85M | -37.54M | -62.02M | -57.78M |
Balance Sheet | ||||||
| Total Assets | 66.48M | 72.06M | 104.61M | 148.33M | 181.29M | 233.14M |
| Cash, Cash Equivalents and Short-Term Investments | 65.00M | 70.04M | 101.15M | 142.82M | 174.30M | 229.79M |
| Total Debt | 15.51M | 15.53M | 15.30M | 15.66M | 16.08M | 15.86M |
| Total Liabilities | 24.33M | 27.81M | 33.60M | 28.53M | 30.28M | 27.40M |
| Stockholders Equity | 42.16M | 44.25M | 71.00M | 119.80M | 151.01M | 205.74M |
Cash Flow | ||||||
| Free Cash Flow | -25.99M | -33.35M | -43.21M | -30.33M | -56.65M | -42.56M |
| Operating Cash Flow | -25.99M | -33.35M | -43.21M | -30.33M | -56.64M | -42.56M |
| Investing Cash Flow | 40.45M | 47.74M | -44.92M | 30.00M | -29.95M | -7.81K |
| Financing Cash Flow | 191.89K | 1.12M | -171.42K | -1.27M | 1.22M | 194.50M |
Aldeyra Therapeutics Technical Analysis
Positive
1.80
Price Trends
1.75
Positive
2.58
Negative
3.81
Negative
Market Momentum
0.12
Negative
63.95
Neutral
80.03
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ALDX, the sentiment is Positive. The current price of 1.8 is below the 20-day moving average (MA) of 1.89, above the 50-day MA of 1.75, and below the 200-day MA of 3.81, indicating a neutral trend. The MACD of 0.12 indicates Negative momentum. The RSI at 63.95 is Neutral, neither overbought nor oversold. The STOCH value of 80.03 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ALDX.
Aldeyra Therapeutics Risk Analysis
Aldeyra Therapeutics disclosed 89 risk factors in its most recent earnings report. Aldeyra Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Aldeyra Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $720.25M | -10.00 | -60.42% | ― | ― | 26.28% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $671.64M | 7.14 | -54.39% | ― | ― | ― | |
49 Neutral | $311.18M | -4.53 | 85.78% | ― | 20.08% | 14.06% | |
48 Neutral | $118.23M | ― | -57.34% | ― | ― | 53.00% | |
47 Neutral | $297.01M | -11.08 | 21.05% | ― | ― | 43.38% | |
42 Neutral | $309.42M | -1.26 | -181.70% | ― | ― | 17.61% |
* Healthcare Sector Average
ALDX
Aldeyra Therapeutics
2.27
-2.08
-47.82%
OMER
Omeros
9.28
6.20
201.30%
GALT
Galectin Therapeutics
4.51
2.36
109.77%
FHTX
Foghorn Therapeutics
5.30
0.52
10.88%
CADL
Candel Therapeutics
9.83
4.84
96.99%
NMRA
Neumora Therapeutics, Inc.
1.67
0.77
85.56%
Aldeyra Therapeutics Corporate Events
Executive/Board ChangesShareholder Meetings
Aldeyra Therapeutics Adds Independent Director, Affirms Governance Support
Positive
Jun 10, 2026
On June 9, 2026, following its annual meeting of stockholders, Aldeyra Therapeutics appointed veteran biotech executive Darlene Deptula-Hicks as a Class III director and Chair of the audit committee, determining that she meets SEC and Nasdaq indep...
Business Operations and StrategyFinancial DisclosuresRegulatory Filings and Compliance
Aldeyra Updates Reproxalap Outlook and Extends Cash Runway
Positive
May 1, 2026
On May 1, 2026, Aldeyra Therapeutics released an updated corporate overview detailing standardized treatment estimates and confidence intervals for the primary endpoints of all proposed commercial dosing regimen efficacy trials of reproxalap in dr...
Executive/Board Changes
Aldeyra Therapeutics Announces Upcoming Board Member Departure
Neutral
Apr 20, 2026
On April 20, 2026, Aldeyra Therapeutics, Inc. announced that Board member Martin J. Joyce has decided not to stand for re-election at the company’s 2026 annual meeting of stockholders and will continue to serve until his term expires at that...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.